pat-gelsinger-just-backed-a-$100-million-challenge-to-nvidia’s-ai-networking-moat.-amd-could-benefit

Pat Gelsinger Just Backed a $100 Million Challenge to Nvidia’s AI Networking Moat. AMD Could Benefit

Former Intel CEO Pat Gelsinger is backing a startup that thinks AI’s next bottleneck is not the accelerator. It is everything waiting for data to arrive. Delos Data announced on September 15 that it raised more than $100 million to develop networking chips and software for increasingly heterogeneous AI data centers. Playground Global, where Gelsinger

Continue Reading
sk-hynix-is-eyeing-intel’s-(intc)-ohio-site.-why-micron-(mu)-should-pay-attention

SK Hynix Is Eyeing Intel’s (INTC) Ohio Site. Why Micron (MU) Should Pay Attention

SK Hynix is exploring something it has never done before: manufacturing memory chips in the United States. Reuters reported on September 16 that the Korean memory giant is discussing several possibilities with Intel Corporation (NASDAQ: INTC ), including leasing part of Intel’s long-delayed Ohio complex or forming a venture involving Intel and large cloud customers.

Continue Reading
how-is-incyte’s-stock-performance-compared-to-other-biotech-stocks?

How Is Incyte’s Stock Performance Compared to Other Biotech Stocks?

Incyte Corp_ office sign-by Bo Shen via iStock Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases. The company’s marketed therapies include JAKAFI for blood cancer, ICLUSIG for leukemia, PEMAZYRE for bile-duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO

Continue Reading